Research Report
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 21, 2014; 20(15): 4370-4376
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4370
Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer
Bun Kim, Soo Jung Park, Jae Hee Cheon, Tae Il Kim, Won Ho Kim, Sung Pil Hong
Bun Kim, Soo Jung Park, Jae Hee Cheon, Tae Il Kim, Won Ho Kim, Sung Pil Hong, Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 120-752, South Korea
Author contributions: Hong SP designed the study; Kim B acquired clinical data and performed the statistical analysis; Park SJ, Cheon JH, Kim TI and Kim WH contributed equally to this study by performing data interpretation and offering important intellectual content; Hong SP and Kim B drafted the manuscript.
Correspondence to: Sung Pil Hong, MD, PhD, Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, South Korea. sphong@yuhs.ac
Telephone: +82-2-22281990 Fax: +82-2-3936884
Received: September 2, 2013
Revised: November 4, 2013
Accepted: January 8, 2014
Published online: April 21, 2014
Core Tip

Core tip: This study identified the clinicopathological features of colorectal cancer (CRC) with BRAF mutation and its molecular interaction with microsatellite instability and KRAS targeting only to stage III/IV CRCs. These molecular markers enable the classification of CRCs into meaningful subtypes for prognosis. Our data strongly support the prognostic role of BRAF mutation in Korean patients with advanced CRC.